Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note published on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ CHEK opened at $2.27 on Friday. Check-Cap has a twelve month low of $1.41 and a twelve month high of $4.63. The stock has a market cap of $13.28 million, a P/E ratio of -0.76 and a beta of 0.45. The company’s 50-day simple moving average is $2.31 and its 200 day simple moving average is $2.39.

Check-Cap (NASDAQ:CHEK) last released its quarterly earnings data on Wednesday, May 15th. The medical research company reported ($0.62) earnings per share for the quarter. Research analysts anticipate that Check-Cap will post -0.68 earnings per share for the current year.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.